Skip to main content
    V

    Vir Biotechnology Inc (VIR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $9.58
    -0.38 (-3.82%)

    Market Cap: $1.71B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Vir Biotechnology Inc (VIR) Earnings: Report Dates and Results

    Updated Nov 4, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Vir Biotechnology (VIR) is expected to report earnings on Feb 22, 2027. In the quarter ended Sep 30, 2026, Vir Biotechnology reported EPS of -$0.57, above the -$0.80 estimate. It beat the EPS estimate in 3 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    41%(12/29)
    Avg Surprise
    +30.73%
    Streak
    1 Q

    Upcoming Estimates

    Reports Feb 22, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.53
    Range-$0.71 - -$0.10
    10 analysts
    Revenue Consensus
    $28.83M
    Range$1.96M - $69.09M
    8 analysts
    Reports May 4, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.44
    Range-$0.66 - -$0.31
    4 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.47+5.3%
    60d ago-$0.43-3.9%
    30d ago-$0.43-3.9%
    7d ago-$0.49+9.9%
    Current-$0.44
    Revenue Consensus
    $17.00M
    Range$500.00K - $50.01M
    3 analysts

    Next Report

    VIR has an expected report date of Feb 22, 2027.

    VIR Earnings Call

    The latest VIR earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 29 quarters below that had an estimate, VIR beat 12 and missed 17. The widest gap in the table came in the quarter ended Sep 30, 2021, when EPS landed 811.11% above the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.57-$0.80-$0.95 - -$0.58+28.75%BeatN/A62 up, 2 downNov 4, 2026N/A
    Jun 30, 2026$0.47$0.83$0.47 - $0.83-43.37%MissN/A40 up, 0 downAug 5, 2026$238.95M
    Mar 31, 2026-$0.85$0.48-$0.59 - $1.06-277.08%MissN/A41 up, 2 downMay 6, 2026N/A
    Dec 31, 2025-$0.31-$0.54-$0.78 - -$0.16+42.59%BeatN/A72 up, 0 downFeb 23, 2026$64.31M
    Sep 30, 2025-$1.17-$0.70-$1.32 - -$0.60-67.14%MissN/A7N/ANov 5, 2025$240000
    Jun 30, 2025-$0.80-$0.72-$0.88 - -$0.54-11.11%MissN/A75 up, 1 downAug 6, 2025$1.21M
    Mar 31, 2025-$0.88-$0.84-$1.03 - -$0.67-4.76%MissN/A60 up, 1 downMay 7, 2025$3.03M
    Dec 31, 2024-$0.76-$0.89-$0.96 - -$0.66+14.61%BeatN/A70 up, 0 downFeb 26, 2025$12.37M
    Sep 30, 2024-$1.56-$1.08-$1.75 - -$0.85-44.44%MissN/A80 up, 0 downOct 31, 2024$2.38M
    Jun 30, 2024-$1.02-$0.89-$1.10 - -$0.54-14.61%MissN/A80 up, 0 downAug 1, 2024$3.08M
    Mar 31, 2024-$0.48-$1.05-$1.32 - -$0.79+54.29%BeatN/A70 up, 0 downMay 2, 2024$56.38M
    Dec 31, 2023-$0.86-$1.01-$1.26 - -$0.40+14.85%BeatN/A90 up, 0 downFeb 22, 2024$16.79M
    Sep 30, 2023-$1.22-$1.19-$1.49 - -$0.88-2.52%Miss-193.8%91 up, 0 downNov 2, 2023$2.64M
    Jun 30, 2023-$1.45-$1.19-$1.55 - -$0.87-21.85%MissN/A91 up, 0 downAug 3, 2023$3.80M
    Mar 31, 2023-$1.06-$0.86-$1.15 - -$0.24-23.26%Miss-127.5%90 up, 0 downMay 4, 2023$62.96M
    Dec 31, 2022-$0.76-$0.39-$1.20 - $0.84-94.87%Miss-119.4%81 up, 0 downFeb 23, 2023$49.41M
    Sep 30, 2022$1.30-$0.31-$1.19 - $1.78+519.35%Beat+58.5%100 up, 1 downNov 3, 2022$374.56M
    Jun 30, 2022-$0.58$0.46-$0.53 - $0.99-226.09%Miss-226.1%81 up, 0 downAug 9, 2022N/A
    Mar 31, 2022$3.85$3.62$1.52 - $5.37+6.35%BeatN/A71 up, 1 downMay 5, 2022$1.23B
    Dec 31, 2021$3.92$3.04-$0.99 - $7.13+28.95%BeatN/A72 up, 0 downFeb 24, 2022$812.75M
    Sep 30, 2021$0.82$0.09-$0.73 - $2.55+811.11%BeatN/A7N/ANov 4, 2021$103.62M
    Jun 30, 2021$0.46-$0.40-$0.95 - $0.92+215.00%BeatN/A7N/AAug 5, 2021$177.07M
    Mar 31, 2021-$1.32-$0.11-$0.88 - $0.86N/AN/AN/A7N/AMay 6, 2021$1.98M
    Dec 31, 2020-$0.83-$0.70-$0.76 - -$0.65-18.57%MissN/A7N/AFeb 25, 2021$1.73M
    Sep 30, 2020-$0.67-$0.60-$0.77 - -$0.23-11.67%MissN/A8N/ANov 10, 2020$1.93M
    Jun 30, 2020-$0.27-$0.62-$0.72 - -$0.49+56.45%BeatN/A5N/AAug 11, 2020$66.99M
    Mar 31, 2020-$0.71-$0.56-$0.60 - -$0.41-26.79%MissN/A5N/AMay 12, 2020$5.72M
    Dec 31, 2019-$0.69-$0.67-$0.81 - -$0.47-2.99%MissN/A4N/AMar 26, 2020$980000
    Sep 30, 2019-$4.60-$3.33-$7.40 - -$0.62-38.14%MissN/A4N/AOct 10, 2019$1.40M
    Jun 30, 2019-$0.51-$0.71N/A+28.17%BeatN/AN/AN/ASep 3, 2019$2.05M
    Last 30 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$3.16, after -$3.82 the year before. It was -$5.80 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$3.16N/A
    Dec 31, 2024-$3.82N/A
    Dec 31, 2023-$4.59-220.5%
    Dec 31, 2022$3.81-1.8%
    Dec 31, 2021$3.88N/A
    Dec 31, 2020-$2.48N/A
    Dec 31, 2019-$5.80N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,300 words across 12 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20264,31412
    2026Q2Jun 30, 20265,66213
    2026Q1Mar 31, 20265,64612
    2025Q4Dec 31, 20258,30116
    2025Q3Sep 30, 20254,53313
    2025Q2Jun 30, 20256,71515
    2025Q1Mar 31, 20256,39613
    2024Q4Dec 31, 20246,98813

    2026Q3 Earnings Call

    Opening remarks

    Kiki Patel Head of Investor Relations Thank you, operator, and welcome, everyone. Earlier today, we issued a press release reporting our third quarter 2026 financial results and corporate update. Before we begin, I'd like to remind everyone that some of the statements we are making today are forward-looking statements under applicable securities laws. Forward-looking statements include, but are not limited to, statements regarding the therapeutic and commercial potential of our clinical and preclinical programs, our development plans and timelines, our collaborations with other companies, our cash runway and capital allocation priorities, and as otherwise described in the legal disclaimers accompanying our public presentations. These forward-looking statements involve substantial risks and uncertainties, which are described in our reports filed with the Securities and Exchange Commission, including our Forms 10-K, 10-Q, and 8-K, and could cause future results, performance, or achievements to differ significantly from those expressed or implied by such forward-looking statements. Joining me on today's call from Vir Biotechnology are Dr. Marianne De Backer, our President and Chief Executive Officer, and Aziz Sawaf, our Chief Financial Officer. The agenda for our call today is as follows: First, Marianne will provide a strategic update on where Vir Bio stands today, including an overview of our Phase III registrational program in hepatitis delta. Next, she will review the latest updates across the PRO-XTEN dual-masked T-cell engager program and present the highlights of our recently announced preclinical collaboration with Gilead. Next, Aziz will review the financial terms of our recent collaboration with Gilead and provide a summary of our third quarter 2026 financial results. And finally, Marianne will close the call, and we'll open the line for Q&A. With that, I'll now turn the call over to Marianne.

    Marianne De Backer President and Chief Executive Officer Thank you, Kiki. Good afternoon, everyone, and thank you for joining us for Vir Biotechnology's Third Quarter 2026 Financial Results Conference Call. We are entering a pivotal period for Vir Bio, with the potential to transform hepatitis delta treatment while building a differentiated oncology franchise. Today, I will highlight significant progress across both those areas and why we believe Vir Bio is well positioned for meaningful value creation ahead. First, we've expanded our leadership team with the addition of Aziz Sawaf as Chief Financial Officer and Dr. David Liu as Chief Medical Officer. Both bring more than 20 years of experience in their respective fields, further bolstering our capabilities as we enter an important period for Vir Bio. With our leadership team strengthened, we are well positioned to execute against the significant opportunities and catalysts ahead. Second, our hepatitis delta program continues to advance through Phase III development.

    Frequently Asked Questions About VIR

    When is Vir Biotechnology's next earnings date?

    Vir Biotechnology's next earnings report is expected for Feb 22, 2027.

    Did VIR beat earnings estimates last quarter?

    Yes. Vir Biotechnology reported EPS of -$0.57 for the quarter ended Sep 30, 2026, above the -$0.80 estimate, a 28.75% surprise.

    What EPS do analysts expect from VIR next quarter?

    The consensus EPS estimate for Vir Biotechnology for the quarter ending Dec 31, 2026 is -$0.53 from 10 analysts, with estimates from -$0.71 to -$0.10.

    How often does VIR beat earnings estimates?

    Vir Biotechnology beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -39.69%.